KUALA LUMPUR (Reuters) – Malaysia’s health ministry said on Tuesday it has given conditional approval for the use of the single-dose antibody cocktail Ronapreve, developed by Regeneron and Roche, to treat COVID-19.
It has also approved a request from Merck & Co for a clinical trial import license for its COVID-19 pill Molnupiravir, to be used as part of studies being conducted in Malaysia, the ministry said in a statement.
(Reporting by Rozanna Latiff; Editing by Ed Davies)
